• 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

 
 

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Please note: The course fee is $10.00 in addition to a $2.50 processing fee which is assessed for all electronic registrations.
 
More information and online registration:  http://academy.isth.org/isth/ 
 
Supported by and unrestricted educational grant from Instrumentation Laboratory
 
Target audience: 

Hematologists and other physicians that are involved in the initial and long-term care of patients diagnosed with acquired TTP. Consultant and training haematologists, nephrologist and molecular pathologists.

Learning objectives: 

At the conclusion of this activity, I will be able to:

  • To be able to understand the pathophysiology of acquired TTP and its relevance to treatment
  • To learn about novel, more targeted approaches to therapy of acquired TTP
  • To be able to recognize the presence of long term complications from a prior diagnosis of TTP including neurocognitive changes, headaches, mood disorders, and vascular complications
  • To better understand the appropriate long-term follow-up for TTP patients to be able to diagnose these long-term complications and assess the risk for relapse
  • Understand the current diagnostic definitions and classification of aHUS and its limitations
  • Understand the diversity of genetic lesions known to result in aHUS
  • Understand the basic laboratory methodologies used to detect these changes and their strengths and limitations
  • Understand the role detection of genetic lesions has in the diagnosis and management of aHUS
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
Yukio Ozaki
 
Speakers:
Spero Cataland
Piers Blombery
 
 
 
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
 BMS/PfizerResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
 Sanofi-Aventis, AlexionSpeaker, Advisory Board
Yukio OzakiThe Sysmex CorporationAdvisory Board
Spero CatalandAblynxConsultant

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.

CME Coordinator Contact Information

Name: 
Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807